Patents by Inventor Liusheng Zhu

Liusheng Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 11970481
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
    Type: Grant
    Filed: October 4, 2023
    Date of Patent: April 30, 2024
    Assignee: NURA BIO, INC.
    Inventors: Jennifer Aiden Kozak, Sean Pomeroy Brown, Christopher Michael Tegley, Alexander Wayne Schammel, Liusheng Zhu, Maximiliano De La Higuera Macias, Shilpa Sambashivan
  • CD73 INHIBITORS
    Publication number: 20240124512
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 18, 2024
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20240116901
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
    Type: Application
    Filed: October 4, 2023
    Publication date: April 11, 2024
    Inventors: Jennifer Aiden KOZAK, Sean Pomeroy BROWN, Christopher Michael TEGLEY, Alexander Wayne SCHAMMEL, Liusheng ZHU, Maximiliano DE LA HIGUERA MACIAS, Shilpa SAMBASHIVAN
  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 11945796
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological diseases.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: April 2, 2024
    Assignee: NURA BIO, INC.
    Inventors: Sean Pomeroy Brown, Keira Garland, Shilpa Sambashivan, Christopher Michael Tegley, Liusheng Zhu
  • CD73 inhibitors
    Patent number: 11807658
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: November 7, 2023
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20230339913
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
    Type: Application
    Filed: August 3, 2021
    Publication date: October 26, 2023
    Inventors: Jennifer Aiden KOZAK, Sean Pomeroy BROWN, Michael Christopher TEGLEY, Alexander Wayne SCHAMMEL, Liusheng ZHU, Maximiliano DE LA HIGUERA MACIAS, Shilpa SAMBASHIVAN
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20230286941
    Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
    Type: Application
    Filed: March 3, 2023
    Publication date: September 14, 2023
    Inventors: Rao KOLLURI, Christopher Michael TEGLEY, Liusheng ZHU, Sean Pomeroy BROWN, Charles Howard REYNOLDS, Andrew Stewart TASKER, Cheryl A. GRICE
  • CD73 INHIBITORS
    Publication number: 20230131747
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 31, 2022
    Publication date: April 27, 2023
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 11629136
    Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: April 18, 2023
    Assignee: NURA BIO, INC.
    Inventors: Rao Kolluri, Christopher Michael Tegley, Liusheng Zhu, Sean Pomeroy Brown, Charles Howard Reynolds, Andrew Stewart Tasker, Cheryl A. Grice
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20230105696
    Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
    Type: Application
    Filed: July 27, 2022
    Publication date: April 6, 2023
    Inventors: Rao KOLLURI, Christopher Michael TEGLEY, Liusheng ZHU, Sean Pomeroy BROWN, Charles Howard REYNOLDS, Andrew Stewart TASKER, Cheryl A. GRICE
  • INHIBITORS OF GLUCOCORTICOID RECEPTOR
    Publication number: 20230096870
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: August 15, 2022
    Publication date: March 30, 2023
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20230052348
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 16, 2023
    Applicant: AMGEN INC.
    Inventors: Sean P BROWN, David Karl BEDKE, Michael R. DEGRAFFENREID, Jiasheng FU, Zhinghong LI, Felix GONZALEZ LOPEZ DE TURISO, Ana GONZALEZ BUENROSTRO, Michael W. GRIBBLE JR., Michael G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Mario G. CARDOZO, Alan C. CHENG
  • CD73 INHIBITORS
    Publication number: 20220411459
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 29, 2020
    Publication date: December 29, 2022
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • CD73 inhibitors
    Patent number: 11530236
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: December 20, 2022
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai, Chien-Hung Yeh
  • CD73 INHIBITORS
    Publication number: 20220220147
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: March 17, 2022
    Publication date: July 14, 2022
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI
  • CD73 inhibitors
    Patent number: 11325938
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: May 10, 2022
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai
  • Compounds that inhibit MCL-1 protein
    Patent number: 11306107
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: April 19, 2022
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, David Karl Bedke, Michael R. Degraffenreid, Jiasheng Fu, Zhihong Li, Felix Gonzalez Lopez De Turiso, Ana Gonzalez Buenrostro, Michael W. Gribble, Jr., Michael G. Johnson, Todd J. Kohn, Kexue Li, Yunxiao Li, Mike Elias Lizarzaburu, Yosup Rew, Joshua Taygerly, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu, Manuel Zancanella, Xian Yun Jiao, Liusheng Zhu, Xianghong Wang, Julio C. Medina, Jason A. Duquette, Jonathan B. Houze, Marc Vimolratana, Mario G. Cardozo, Alan C. Cheng
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20220081417
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological diseases.
    Type: Application
    Filed: September 15, 2021
    Publication date: March 17, 2022
    Inventors: Sean Pomeroy Brown, Keira Garland, Shilpa Sambashivan, Christopher Michael Tegley, Liusheng Zhu
  • GLUCOCORTICOID RECEPTOR MODULATORS
    Publication number: 20220079924
    Abstract: Described herein are glucocorticoid receptor modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: October 9, 2019
    Publication date: March 17, 2022
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Yosup REW, Daqing SUN, Qiuping YE, Haiying ZHOU, Hiroyuki KAWAI, Jared MOORE, Johnny PHAM, Kejia WU, Liusheng ZHU
  • Inhibitors of glucocorticoid receptor
    Patent number: 11208432
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: December 28, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Haiying Zhou, Minna Delarae Balbas, Valeria R. Fantin